| Abstract
| - With emerging sophistication in the exploration of ocean environment,a number of marine bioactive products have been identified with promisinganticancer activity. Many of these are in active phase I or phaseII clinical trials or have been terminated because of adverse sideeffects, mainly hematological in nature. Nonetheless, the informationderived has aided enormously in providing leads for laboratory synthesiswith modifications in the parent structure affecting compound solubility,absorption, and toxicity, resulting in less severe toxicity whileachieving maximum efficacy in smaller doses. We describe herein, afew of the compounds obtained from marine and terrestrial sources[bryostatin 1 (1), dolastatin 10 (2), auristatinPE (3), and combretastatin A4 (4)] thathave been extensively investigated in our laboratory and continueto be investigated for their sensitization effects with other cytotoxicagents in several different site-specific tumors employing murinemodels or human subjects.
|
